From poison to lifeline – how my views on chemotherapy changed as a cancer patientCancer survivor Brooke Gant tells us about her experiences with chemotherapy. In 2017, I started off being a Share XFrom poison to lifeline – how my views on chemotherapy changed as a cancer patienthttps://pharmaphorum.com/views-analysis-patients/from-poison-to-lifeline-how-my-views-on-chemotherapy-changed-as-a-cancer-patient/
J&J gets US okay for first targeted bladder cancer drugJohnson & Johnson’s Balversa has become the first targeted therapy for bladder cancer after an FDA approval at Share XJ&J gets US okay for first targeted bladder cancer drughttps://pharmaphorum.com/news/jj-gets-us-okay-for-first-targeted-bladder-cancer-drug/
EU regulators to fast-track Janssen’s multiple myeloma CAR-TEuropean regulators are to hasten development of Janssen’s CAR-T therapy for patients with multiple myeloma, after promising early-stage Share XEU regulators to fast-track Janssen’s multiple myeloma CAR-Thttps://pharmaphorum.com/news/eu-regulators-to-fast-track-janssens-multiple-myeloma-car-t/
Fusion raises $105m for radiopharmaceutical trialsRadiopharmaceuticals are already well established in imaging technology for a range of diseases – but their use to Share XFusion raises $105m for radiopharmaceutical trialshttps://pharmaphorum.com/news/fusion-raises-105m-towards-radiopharmaceutical-trials/
Clovis’ Rubraca is latest PARP drug showing promise in pancreatic cancerClovis Oncology’s Rubraca has become the latest PARP drug to show potential in pancreatic cancer, as pharma companies Share XClovis’ Rubraca is latest PARP drug showing promise in pancreatic cancerhttps://pharmaphorum.com/news/clovis-rubraca/
NICE recommends interim funding for Lilly’s breast cancer drugFinal draft guidance from NICE has recommended interim NHS funding for Eli Lilly’s Verzenios (abemaciclib) with fulvestrant, giving Share XNICE recommends interim funding for Lilly’s breast cancer drughttps://pharmaphorum.com/news/nice-recommends-interim-funding-for-lillys-breast-cancer-drug/
AZ signs multi-billion cancer R&D deal with Daiichi SankyoAstraZeneca is to raise $3.5 billion to fund a global development and marketing collaboration with Daiichi Sankyo, for Share XAZ signs multi-billion cancer R&D deal with Daiichi Sankyohttps://pharmaphorum.com/news/az-signs-multi-billion-cancer-rd-deal-with-daiichi-sankyo/
AZ gets NICE nod for ‘big advance’ Imfinzi in lung cancerAstraZeneca has won the backing of NICE for its cancer immunotherapy Imfinzi for non-small cell lung cancer (NSCLC), Share XAZ gets NICE nod for ‘big advance’ Imfinzi in lung cancerhttps://pharmaphorum.com/news/az-gets-nice-nod-for-big-advance-imfinzi-in-lung-cancer/
GSK mulls filings for multiple myeloma drugGlaxoSmithKline has announced more data making the case for its multiple myeloma antibody-drug conjugate GSK2857916, confirming that almost Share XGSK mulls filings for multiple myeloma drughttps://pharmaphorum.com/news/gsk-mulls-filings-for-multiple-myeloma-drug/
